Workup and Treatment for Suspected Anti-IgLON5 Disease
For suspected anti-IgLON5 disease, immediately test for anti-IgLON5 antibodies in both serum and CSF using cell-based assays, perform comprehensive sleep studies including polysomnography, obtain brain MRI, and initiate combination immunotherapy with corticosteroids plus IVIG or plasma exchange rather than monotherapy, as combination therapy achieves response rates of 66.6% versus only 31.8% with monotherapy 1.
Diagnostic Workup Algorithm
Initial Clinical Recognition
Look for this characteristic constellation that distinguishes anti-IgLON5 from other neurodegenerative disorders:
- Sleep disturbances (most common): NREM parasomnia with finalistic movements, severe insomnia, obstructive sleep apnea, stridor 2
- Bulbar symptoms: dysphonia, dysarthria, dysphagia, vocal cord paralysis (67% develop bilateral vocal cord paralysis) 3
- Movement abnormalities: gait instability, ataxia, orofacial myorhythmia, fasciculations 4, 2
- Oculomotor findings: horizontal gaze limitation, slow saccades, impaired vestibulo-ocular reflex 4
- Autonomic dysfunction: severe orthostatic hypotension, urinary incontinence 5
Critical pitfall: This disease mimics PSP, MSA, and corticobasal syndrome but has potentially treatable autoimmune components 6, 5.
Laboratory and Imaging Studies
Essential tests (following general autoimmune encephalitis guidelines 7):
- Antibody testing: Anti-IgLON5 IgG in both serum AND CSF via cell-based assays 5
- CSF analysis: Cell count, protein, oligoclonal bands, IgG index to document inflammation 7
- HLA typing: Check for HLA-DRB110:01 and HLA-DQB105:01 (strongly associated) 2, 1
- Brain MRI: Often unremarkable, but rules out other pathology 4
- Polysomnography: Essential for documenting characteristic sleep abnormalities 3
- Serum GFAP: May be elevated 4
- Cancer screening: CT chest/abdomen/pelvis as per autoimmune encephalitis protocols 7
Important nuance: CSF inflammation predicts better treatment response 1, so document this carefully.
Airway Assessment
This is life-threatening: 78.5% of patients with respiratory symptoms require tracheotomy 3.
- Perform urgent otolaryngological evaluation with laryngoscopy
- Assess for vocal cord mobility (can deteriorate rapidly even if initially normal)
- Consider early tracheotomy in patients with dysphagia, stridor, or sleep-disordered breathing to prevent sudden death 3
Treatment Strategy
First-Line Immunotherapy
Start combination therapy immediately once infection is ruled out 7:
- High-dose IV methylprednisolone (1g daily × 3-5 days) PLUS
- IVIG (2g/kg divided over 2-5 days) OR plasma exchange (5-10 sessions)
Rationale: Combination therapy from the start is superior to sequential monotherapy (66.6% vs 31.8% response rate) 1. While general autoimmune encephalitis guidelines suggest starting with corticosteroids alone for less severe cases 7, anti-IgLON5 disease has limited response to monotherapy and warrants aggressive initial treatment 2, 1.
Choose PLEX over IVIG if: Severe hyponatremia, high thromboembolism risk, or associated demyelination 7. Choose IVIG if: Patient is agitated or has bleeding disorders 7.
Second-Line Therapy
If no improvement after 2-4 weeks of combined first-line therapy 7:
- Azathioprine (100% response rate in limited data) 1
- Mycophenolate mofetil (75% response rate) 1
- Rituximab (for antibody-mediated component) 7
Evidence strength: Second-line therapy achieves 53.8% response versus only 32.6% with first-line alone 1, supporting escalation in non-responders.
Maintenance Therapy
Initiate bridging therapy to prevent relapse 7:
- Gradual oral prednisone taper, OR
- Monthly IV methylprednisolone, OR
- Monthly IVIG
Predictors of Better Response
Patients more likely to respond to immunotherapy 1:
- Cognitive impairment or non-classical phenotypes
- HLA-DQB105:01 WITHOUT HLA-DRB110:01
- CSF inflammation present
- Earlier treatment initiation
Critical observation: The 2024 case report 4 demonstrates that some patients have excellent response to glucocorticoid monotherapy, suggesting a phenotypic spectrum where autoimmunity predominates over tauopathy in certain individuals. However, you cannot predict this prospectively, so start with combination therapy.
Mortality Considerations
Aggressive immunotherapy increases survival 2. Patients receiving only IV corticosteroids or no treatment have higher mortality than those receiving more potent immunotherapy. This directly impacts the morbidity and mortality outcomes that should guide all treatment decisions.
Common Pitfalls
- Misdiagnosing as PSP or MSA: Anti-IgLON5 can present identically but is potentially treatable 6, 5
- Delaying tracheotomy: Vocal cord paralysis can develop suddenly; early intervention prevents death 3
- Using monotherapy: Substantially inferior response rates 1
- Stopping treatment prematurely: This disease requires prolonged immunosuppression 2
- Missing the diagnosis in "atypical" presentations: The clinical spectrum continues to expand 8, 4